glp-1 agonist weight loss comparison Comparing GLP-type therapies for in those without diabetes. Two glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (#semaglutide and #liraglutide) and one dual (#tirzepatide) have been FDA-approved for #weightloss in adults Comparison of short-acting versus long-acting
Description
It often is over time
Preliminary Phase I trials have shown a differentiating clinical profile for ECC5004, with good tolerability and encouraging glucose and body weight reduction across the dose levels tested compared to placebo
The cardiovascular effects of GLP-1 can be seen as an extension of its role in maintaining metabolic homeostasis
But its getting more attention because some people on GLP-1 drugs developed the condition
Insulin promotes glucose uptake into cells, including fat cells, and the improved metabolic control often leads to increased caloric storage
Vasu P, Dorairaj EA, Weinreb RN, Huang AS, Dorairaj SK
